PainReform (NASDAQ:PRFX – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Risk & Volatility
PainReform has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Insider & Institutional Ownership
37.3% of PainReform shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for PainReform and Contineum Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
| Contineum Therapeutics | 1 | 2 | 2 | 0 | 2.20 |
Contineum Therapeutics has a consensus target price of $21.40, indicating a potential upside of 146.54%. Given Contineum Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than PainReform.
Profitability
This table compares PainReform and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PainReform | N/A | N/A | N/A |
| Contineum Therapeutics | N/A | -25.48% | -24.28% |
Valuation and Earnings
This table compares PainReform and Contineum Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PainReform | $20,000.00 | 20.70 | -$5.02 million | ($736.66) | -0.00 |
| Contineum Therapeutics | $50.00 million | 6.82 | -$59.98 million | ($1.77) | -4.90 |
PainReform has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
Summary
PainReform beats Contineum Therapeutics on 8 of the 13 factors compared between the two stocks.
About PainReform
PainReform Ltd. is an Israel-based specialty pharmaceutical company developing treatments for postoperative pain. Its lead candidate, PRF-110, is an extended-release formulation of the local anesthetic ropivacaine designed for administration at a surgical site to provide pain relief after surgery. The company’s development work has focused on evaluating PRF-110 for postoperative pain management in procedures including bunion surgery and hernia repair. PainReform’s research centers on drug-delivery approaches intended to extend the effect of local anesthetics.
About Contineum Therapeutics
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics. Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
